On Monday, GABA Therapeutics commenced dosing for its phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia. The phase I, two-stage, double-blind, placebo-controlled single and multiple dose study is evaluating the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy volunteers.
GABA Therapeutics commences phase I study of Etifoxine
January 16, 2020
Articles
7:21 pm
JOIN OUR MAILING LIST
Sign up to receive the latest news on atai.
Email